ERBB2 and breast cancer: There are different ongoing clinical trials concerning HR-positive/HER-positive metastatic BC testing new molecules (such as pyrotinib, a new TKI against HER2, or dalpiciclib, a new CDK4/6I) and combinations, and they are summarized in Table 1.